Medindia
Advertisement

Patients With Advanced Myelofibrosis Tolerate PRM-151 Therapy Well

by Himabindu Venkatakrishnan on December 10, 2014 at 11:20 AM
Font : A-A+

 Patients With Advanced Myelofibrosis Tolerate PRM-151 Therapy Well

The potential of the compound PRM-151 for reducing progressive bone marrow fibrosis (scarring) in patients with advanced myelofibrosis has been investigated. The study showed initial positive results. Myelofibrosis is a life-threatening bone marrow cancer.

The study, led by Srdan Verstovsek, M.D., Ph.D., professor of leukemia at The University of Texas MD Anderson Cancer Center, showed the compound was well tolerated in observing 27 patients. Verstovsek's research results were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) annual conference in San Francisco and were published in the ASH journal Blood.

Advertisement

"There was no evidence of drug-related myelosuppression or suppression of the bone marrow's ability to produce blood cells and platelets. We also saw encouraging trends in both clinical and histologic aspects of the disease," said Verstovsek. "With demonstrated reduction in bone marrow fibrosis, stable to improved hematologic parameters, symptom responses, and stable to reduced spleen size, it is clear that there is merit for further development of PRM."

Myelofibrosis is caused by the accumulation of malignant bone marrow cells that triggers an inflammatory response, scarring the bone marrow and limiting its ability to produce blood, resulting in anemia. About 3,000 new cases of myelofibrosis are diagnosed in the United States each year. Average survival ranges from two to 11 years, depending on a variety of prognostic factors.
Advertisement

Patients with myelofibrosis experience many debilitating symptoms including fatigue, weight loss, abdominal pain, severe itching, night sweats and bone pain. A swollen spleen is one hallmark of the disease tied to many of its symptoms.

PRM is a recombinant form of Pentraxin-2, a human protein that acts at sites of tissue damage, inducing macrophage differentiation to prevent and reverse fibrosis. PRM has demonstrated broad anti-fibrotic activity in multiple preclinical models of established fibrotic diseases and no dose-limiting toxicities in phase I trials. Verstovsek found that PRM was well tolerated both in combination with, and without ruxolitinib, another potent myelofibrosis therapy.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Sedentary Behavior Precipitates Night-Time Hot Flashes
Gonorrhea
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Reiki and Pranic Healing 

Recommended Reading
Clinical Trial Using Stem Cell in Parkinson's Disease - Likely in Near Future
Transplantation of dopaminergic neurons by stem cells can produce relief for patients with ......
Bone Marrow Aspiration and Biopsy
Bone marrow biopsy and aspiration is the removal of some bone marrow tissue for diagnosis and ......
Comparison of Outcomes of Peripheral and Bone Marrow Stem Cells Transplantation
Bone marrow transplant was first done successfully in 1968. The surgical procedure is required for ....
Bone Marrow Transplantation - Animation
Animation and slides providing graphic explanation of Bone Marrow Transplantation (BMT)/Stem Cell ....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use